The UK and US have hammered out a important trade agreement that will keep no import taxes on British medicine products being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise expenditure on pharmaceuticals through the NHS. This pledge ensures that duties on these vital exports will stay at zero for a period of three years.
This agreement follows previous warnings to significantly raise duties on branded drug products, with increases floated as high as one hundred percent.
"This deal between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," a release declared.
Economic Importance
Pharmaceuticals represent one of the Britain's biggest export categories to the United States, which is clearly the largest market for leading British pharmaceutical firms.
Statistics reveal that in the one-year period leading up to last September, the UK shipped medicines totaling over eleven billion pounds to the US. This amount made up 17.4% of total UK exports in that timeframe.
"This guarantee protects employment, increases investment and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The pact involves several notable commitments from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to double overall public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. Last year, repayments topped twenty percent.
Recent Tensions
The deal comes amid a protracted dispute between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were intensified by claims that US patients were charged a premium for the equivalent treatments than patients in the other developed nations.
In recent months, several large manufacturing plans in the UK have been delayed or abandoned, while major funding commitments have been announced toward US facilities.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
